The Science of Cardiovascular Intervention
Medinol is dedicated to the science of cardiovascular intervention. For over 20 years, our in-house research, development, andhave continuously raised the bar for quality and performance of stenting systems. With over two million stents delivered to date, our cutting-edge cardiovascular intervention technology continues to demonstrate extraordinary clinical results, and our products constantly stretch the limits of innovation.
The scientific spirit that led us to pioneer the revolutionary NIR stent in 1996 still drives our multidisciplinary team today. Our uncompromising devotion to clinical achievement powered the creation of our current products, shapes our rich product roadmap and drives the growth of our intellectual property portfolio.
Outstanding Products and Technologies
Medinol develops, manufactures, and markets the industry-leading NIRxcell™ Bare Metal Stent (BMS). Made from thin cobalt-chrome alloy and recognized for its unique flexibility, conformability and scaffolding, NIRxcell has a dramatically lower rate of restenosis (blood vessel re-narrowing) compared to competing stents in a recent clinical study.
NIRxcell features the revolutionary Flexx²™ catheter technology with a spring-tip that eliminates tip flare-out and buckling. Flexx² overcomes traditional polymer tip limitations, offering simultaneously better flexibility and better crossability, resulting in unprecedented ease-of-delivery even in tough anatomies.
Medinol’s eDES™ – an elastomer-based Drug-Eluting Stent technology (currently in clinical studies) - leverages the proven NIRxcell stent design and delivery system to offer a new level of uniform elution and stent surface integrity.
All of our cardiovascular intervention solutions are manufactured in-house using our proprietary QualitySurface™ manufacturing technology. This unique manufacturing method enables Medinol to conduct strict and automated quality control on each individual stent, ensuring consistently exceptional product quality and safety.
Founded in 1992 by Dr. Judith Richter and Dr. Jacob (Kobi) Richter, Medinol today continues to benefit from the leadership and scientific insight of its founders, and has earned an international reputation for innovation, quality and integrity.
Privately-held, the full scope of Medinol’s activity - including research, development, quality control, regulatory affairs, clinical trials, manufacturing, marketing and sales – is conducted in-house.
The experienced Medinol management team brings diverse experience with proven records of success in a wealth of scientific and engineering fields applied to medical devices. Our diverse and multidisciplinary research team boasts broad experience in physics, mechanical engineering, chemistry, biology, materials and pharmaceutics. Together, we constitute a creative, caring and motivated industry-leading force.